Literature DB >> 21996730

Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.

J Y Leung1, E R Andrechek, R D Cardiff, J R Nevins.   

Abstract

A hallmark of human cancer is heterogeneity, reflecting the complex series of changes resulting in the activation of oncogenes coupled with inactivation of tumor suppressor genes. Breast cancer is no exception and indeed, many studies have revealed considerable complexity and heterogeneity in the population of primary breast tumors and substantial changes in a recurrent breast tumor that has acquired metastatic properties and drug resistance. We have made use of a Myc-inducible transgenic mouse model of breast cancer in which elimination of Myc activity following tumor development initially leads to a regression of a subset of tumors generally followed by de novo Myc-independent growth. We have observed that tumors that grow independent of Myc expression have gene profiles that are distinct from the primary tumors with characteristics indicative of an epithelial-mesenchymal transition (EMT) phenotype. Phenotypic analyses of Myc-independent tumors confirm the acquisition of an EMT phenotype suggested to be associated with invasive and migratory properties in human cancer cells. Further genomic analyses reveal mouse mammary tumors growing independent of myc have a higher probability of exhibiting a gene signature similar to that observed for human 'tumor-initiating' cells. Collectively, the data reveal genetic alterations that underlie tumor progression and an escape from Myc-dependent growth in a transgenic mouse model that can provide insights to what occurs in human cancers as they acquire drug resistance and metastatic properties.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21996730      PMCID: PMC3356601          DOI: 10.1038/onc.2011.433

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

3.  A bayesian analysis strategy for cross-study translation of gene expression biomarkers.

Authors:  Joseph Lucas; Carlos Carvalho; Mike West
Journal:  Stat Appl Genet Mol Biol       Date:  2009-02-04

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Authors:  Chad J Creighton; Xiaoxian Li; Melissa Landis; J Michael Dixon; Veronique M Neumeister; Ashley Sjolund; David L Rimm; Helen Wong; Angel Rodriguez; Jason I Herschkowitz; Cheng Fan; Xiaomei Zhang; Xiaping He; Anne Pavlick; M Carolina Gutierrez; Lorna Renshaw; Alexey A Larionov; Dana Faratian; Susan G Hilsenbeck; Charles M Perou; Michael T Lewis; Jeffrey M Rosen; Jenny C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-03       Impact factor: 11.205

6.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.

Authors:  Robert B Boxer; Joanne W Jang; Louis Sintasath; Lewis A Chodosh
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

7.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.

Authors:  C M D'Cruz; E J Gunther; R B Boxer; J L Hartman; L Sintasath; S E Moody; J D Cox; S I Ha; G K Belka; A Golant; R D Cardiff; L A Chodosh
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

8.  Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras.

Authors:  Katrina Podsypanina; Katerina Politi; Levi J Beverly; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-20       Impact factor: 11.205

9.  Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.

Authors:  Susan E Moody; Christopher J Sarkisian; Kristina T Hahn; Edward J Gunther; Steven Pickup; Katherine D Dugan; Nathalie Innocent; Robert D Cardiff; Mitchell D Schnall; Lewis A Chodosh
Journal:  Cancer Cell       Date:  2002-12       Impact factor: 31.743

10.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  10 in total

1.  TEAD activity is restrained by MYC and stratifies human breast cancer subtypes.

Authors:  Dana Elster; Laura A Jaenicke; Martin Eilers; Björn von Eyss
Journal:  Cell Cycle       Date:  2016-07-19       Impact factor: 4.534

2.  Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Authors:  Randy S Schrecengost; Staci N Keller; Matthew J Schiewer; Karen E Knudsen; Charles D Smith
Journal:  Mol Cancer Res       Date:  2015-08-13       Impact factor: 5.852

3.  Combined analysis of copy number alterations by single-nucleotide polymorphism array and MYC status in non-metastatic breast cancer patients: comparison according to the circulating tumor cell status.

Authors:  R Nadal; M Salido; L Nonell; M Rodríguez-Rivera; E Puigdecanet; J L Garcia-Puche; M Macià; J M Corominas; M J Serrano; J A Lorente; F Solé
Journal:  Tumour Biol       Date:  2014-10-07

4.  Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2.

Authors:  Benjamin Cieply; Joshua Farris; James Denvir; Heide L Ford; Steven M Frisch
Journal:  Cancer Res       Date:  2013-08-13       Impact factor: 12.701

Review 5.  Targeting RNA polymerase I to treat MYC-driven cancer.

Authors:  G Poortinga; L M Quinn; R D Hannan
Journal:  Oncogene       Date:  2014-03-10       Impact factor: 9.867

6.  A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer.

Authors:  Daniel P Hollern; Eran R Andrechek
Journal:  Breast Cancer Res       Date:  2014-06-05       Impact factor: 6.466

7.  Linking imaging to omics utilizing image-guided tissue extraction.

Authors:  Jonathan A Disselhorst; Marcel A Krueger; S M Minhaz Ud-Dean; Ilja Bezrukov; Mohamed A Jarboui; Christoph Trautwein; Andreas Traube; Christian Spindler; Jonathan M Cotton; Dieter Leibfritz; Bernd J Pichler
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-05       Impact factor: 11.205

8.  Negative Selection and Chromosome Instability Induced by Mad2 Overexpression Delay Breast Cancer but Facilitate Oncogene-Independent Outgrowth.

Authors:  Konstantina Rowald; Martina Mantovan; Joana Passos; Christopher Buccitelli; Balca R Mardin; Jan O Korbel; Martin Jechlinger; Rocio Sotillo
Journal:  Cell Rep       Date:  2016-06-09       Impact factor: 9.423

9.  Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.

Authors:  Daniel P Hollern; Matthew R Swiatnicki; Eran R Andrechek
Journal:  PLoS Genet       Date:  2018-01-18       Impact factor: 5.917

10.  MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.

Authors:  Jessica C Casciano; Caroline Perry; Adam J Cohen-Nowak; Katelyn D Miller; Johan Vande Voorde; Qifeng Zhang; Susan Chalmers; Mairi E Sandison; Qin Liu; Ann Hedley; Tony McBryan; Hsin-Yao Tang; Nicole Gorman; Thomas Beer; David W Speicher; Peter D Adams; Xuefeng Liu; Richard Schlegel; John G McCarron; Michael J O Wakelam; Eyal Gottlieb; Andrew V Kossenkov; Zachary T Schug
Journal:  Br J Cancer       Date:  2020-01-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.